Biomatter Manipulation Technologies Group

Engineered 3D human tissue models are have emerged as a powerful tool for the pharmaceutical industry, as well as in infectious disease and cancer research.

The Biomatter Manipulation Technology Group (BMTG) is focused on integrating advances from multiple disciplines to develop new technologies to address challenges in human health and performance-related research.

More concretely, we develop, improve, and apply biomaterials, and biofabrication tools to create in vitro tissue models with advanced architectures, improved reproducibility, and reduced cost with the goal of accelerating bioscience research and medicine.

We are developing novel biomaterials to support multiple 3D bioprinting technologies as well as novel bioreactor designs to aid in 3D tissue fabrication, maturation, and exposure to various and unique pathological challenges and pharmaceutical therapies.

We believe that a multi-pronged approach, concurrently developing bioprinting, biomaterials, and bioreactors (with input from developmental biology), allows for the integration of technologies into a larger vision for a more significant impact.

By developing them in step with each other, the weaknesses and limitations of any individual technology can be compensated for by a modification in another. Importantly these changes can be made early in the development cycle.